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Chronic urticaria (CU) is a common condition charac-
terized by daily or almost daily occurrence of wheals, 
angioedema, or both over a period of more than 6 weeks 
(1). CU is classified into inducible (CIndU) and sponta-
neous forms (CSU). 
The annual period prevalence of CSU was recently es-
timated in an Italian cohort as between 0.02% and 0.38%, 
whereas a German study showed a lifetime prevalence 
of CU at 1.8% (2, 3). While an association between CU 
and certain autoimmune diseases is well-established (3), 
CSU was surprisingly associated with obesity in a recent 
Italian study (4). Moreover, in a South Korean cohort of 
131 patients with CU, metabolic syndrome was present 
in 30% of patients, and these individuals had particularly 
poor clinical outcomes and a more severe disease course 
(5). Finally, a population-based Taiwanese study of 9798 
adults with CU recently showed that the condition was 
significantly associated with having received a prior 
diagnosis of hyperlipidaemia (6). 
Despite the above observations, no study has examined 
a possible association between CU and cardiovascular 
(CV) disease. We therefore investigated the risk of myo-
cardial infarction (MI), ischaemic stroke, CV death, and 
major adverse CV events (MACE; a composite of MI, 
ischemic stroke, and CV death), in patients with CU 
and CIndU, respectively, in a nationwide cohort using 
prospectively collected administrative data.
MATERIALS AND METHODS (for complete details 
see Appendix S11)
Data sources and study population
Study approval ref. 2007-58-0015; approval from an ethics com-
mittee is not required for register studies in Denmark. Danish 
nationwide administrative registers were linked at individual-level, 
including the Danish Register of Medicinal Products Statistics 
(records all pharmacy-dispensed prescriptions), the National 
Patient Registry (contains data on all in- and outpatient hospital 
contacts, and hospital administered medication), and the National 
Causes of Death Registry (records causes of deaths). Information 
on income is recorded by Statistics Denmark. 
We identified all patients aged 18 years or older with a first-
time diagnosis of CU between 1 January 1997 and 31 December 
2012. The index date for cases was the date of first diagnosis, and 
patients were matched 1:30 with healthy controls. Index date for 
controls was the index date for the corresponding cases, and the 
cohort was followed until migration, death from any cause, or the 
occurrence of an endpoint, whichever came first. A study flow chart 
is available in Fig. S11. The primary endpoints were a diagnosis of 
MI, ischemic stroke, CV death, and MACE, respectively. 
Covariates
Baseline treatment up to 6 months before study inclusion was 
defined for azathioprine, cholesterol lowering drugs, cyclosporine, 
methotrexate, montelukast, and omalizumab. Baseline comorbidity 
was assessed up to 5 years prior to study inclusion for alcohol 
abuse, cardiovascular disease, diabetes, and hypertension. We 
calculated an index of socioeconomic status (standardized by age) 
between 0 (lowest) and 4 (highest) based on the average gross 
annual income during a 5-year period before study inclusion. 
Statistical analysis
We described baseline characteristics with means and standard 
deviations for continuous variables and frequencies and percen-
tages for categorical variables. Incidence rates were summarized 
per 1,000 person-years, and Cox regression analyses were perfor-
med to estimate crude and fully adjusted (adjusted for age, sex, 
socio-economic status, medication, and comorbidity) hazard ratios 
(HRs), respectively. Model assumptions were tested and found 
to be valid. p < 0.05 was considered significant and results were 
reported with 95% confidence intervals (CIs) where applicable. 
All analyses were performed using SAS v9.4 and STATA v13.0. 
Presentation of data on less than 3 individuals is not permitted, 
thus results of 1 or 2 events or individuals are shown as < 3.
RESULTS
After excluding patients with incomplete information 
due to migration, the final study population comprised 
a total of 2,215 patients with CU, and 66,203 age- and 
sex-matched controls. Similarly, for CIndU we identi-
fied 977 study cases and 28,497 corresponding controls. 
The baseline characteristics are shown in Table SI1, and 
characteristics were generally similar between cases 
and controls, albeit with a slightly higher prevalence of 
hypertension and cardiovascular disease among study 
cases at baseline.
The incidence rates were generally comparable 
between cases and controls (Table I), and after ad-
justment for potential confounding factors, there was 
no significantly increased risk of MI (adjusted HR 
1.18 [0.79–1.76]), ischaemic stroke (adjusted HR 1.03 
[0.70–1.52]), CV death (adjusted HR 0.67 [0.39–1.17]), 
or MACE (adjusted HR 1.09 [0.83–1.42]), respectively. 
Similarly, there was no increased risk in any of the study 
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outcomes in patients with CIndU, as shown in Table I. 
When analyses were limited to patients with CSU, there 
were no significant changes to any of the observed results 
(data not shown).
DISCUSSION
In our nationwide cohort, we found no association 
between CU and CV disease. The same was the case in 
analyses of patients CIndU patients only. While altera-
tions in lipid metabolism and obesity could play a role 
in the aetiopathogenesis of CU, there appears to be no 
relationship with CV comorbidity. It is possible that the 
relatively short disease duration in patients with CU is 
insufficient to generate putative arteriosclerosis from sys-
temic low-grade inflammation. Indeed, other chronic skin 
conditions that have been associated with CV disease, 
such as psoriasis (13) and hidradenitis suppurativa (12), 
are characterized by a more persistent course. Certain 
limitations and strengths apply to the present study. 
While our study benefited from the nationwide design, 
patients were limited to those seen in a hospital setting, 
which may represent a selected population. Moreover, 
we lacked information regarding disease severity, and 
constitutional factors, such as body mass index (BMI), 
potentially obscuring an association with CU. However, 
since recent studies have associated CU with obesity, 
this would arguably have resulted in an overestimation 
of the true CU-associated risk. Also, we were unable 
to examine the effect of disease duration on the risk of 
adverse CV outcomes. In addition, while the maximum 
follow-up was 31 December 2012, omalizumab was not 
approved for use in CU at that time, and we are therefore 
unable to determine the potential effects of omalizumab 
on the CV risk. Lastly, the Danish population is predomi-
nantly Caucasian, which may limit extrapolation to other 
ethnicities. In conclusion, while we did not observe any 
increased CV risk in patients with CU or CIndU, further 
studies are warranted to confirm our findings. 
Conflicts of interest: KK has served as an advisory board member 
for Novartis and received research grants from Novartis. CV has 
received fees as a speaker from Novartis and is a Novartis advisory 
board member.
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Table I. Follow-up time, number of events, incidence rates, and hazard ratios (HR) of myocardial infarction, ischaemic stroke, cardiovascular 
death, and major adverse cardiovascular events, respectively (for complete details see Table SII1)
Chronic urticaria Inducible urticaria
Controls Cases Controls Cases
Cardiovascular death
Follow-up time, years 386,965 13,152 185,666 6,308
Number of events 526 13 153 4
Incidence rate/1,000 person-years (95% confidence interval) 1.36 (1.25–1.48) 1.00 (0.57–1.70) 0.82 (0.70–0.97) 0.63 (0.24–1.69)
Unadjusted HR (95% confidence interval) 0.73 (0.42–1.26, p = 0.26) 0.77 (0.28–2.07, p = 0.60)
Adjusted HR (95% confidence interval, p-value) 0.67 (0.39–1.17, p = 0.16) 0.63 (0.23–1.72, p = 0.37)
Major adverse cardiovascular events
  Follow-up time, years 382,956 13,013 183,999 6,260
  Number of events 1.514 57 543 16
  Incidence rate/1,000 person-years (95% confidence interval) 3.95 (3.76–4.16) 4.38 (3.38–5.68) 2.95 (2.71–3.21) 2.56 (1.57–4.17)
  Unadjusted HR (95% confidence interval) 1.11 (0.86–1.44, p = 0.45) 0.87 (0.53–1.42, p = 0.57)
  Adjusted HR (95% confidence interval, p-value) 1.09 (0.83–1.42, p = 0.54) 0.76 (0.46–1.25, p = 0.27)
